The Drug That Outperformed Ozempic — What CagriSema Actually Is
Cagrilintide + semaglutide hit two appetite pathways at once. Here's what the REDEFINE trials found — and where FDA approval stands.
I now have everything I need. Let me write the article.
The Drug That Outperformed Ozempic — What CagriSema Actually Is
Most weight-loss drugs work one way. CagriSema works two ways at once — and the early numbers are turning heads.
Novo Nordisk's experimental combination pairs cagrilintide (an amylin analogue) with semaglutide (the active ingredient in Wegovy and Ozempic). The idea: stack two separate appetite-suppressing signals so the brain and gut get hit from different angles simultaneously. The result, at least in the Phase 3 REDEFINE trials, looks like a meaningful step beyond what semaglutide alone delivers.
Here's what the research actually says.
Two Hormones, One Injection
Semaglutide mimics GLP-1, a gut hormone that slows digestion and signals fullness to the brain. The FDA's Wegovy label confirms it's approved for long-term weight reduction in adults and adolescents with obesity, and for reducing cardiovascular risk in adults with overweight or obesity who have established heart disease.
Cagrilintide is a different animal entirely. It's a long-acting analogue of amylin — a hormone your pancreas releases alongside insulin after a meal. Amylin tells your brain the meal is over. On its own, it produces modest weight loss. But when you combine it with a GLP-1 receptor agonist, the two signals appear to amplify each other through complementary pathways.
A 2024 systematic review and meta-analysis in Indian Journal of Endocrinology and Metabolism examined the efficacy and safety of cagrilintide alone and in combination with semaglutide, concluding that the combination showed meaningful advantages over either agent used alone.
What the REDEFINE Trials Found
The big news dropped in August 2025 with the publication of two landmark Phase 3 trials in the New England Journal of Medicine.
The REDEFINE 1 trial, which studied adults with overweight or obesity (without type 2 diabetes), found that coadministered cagrilintide and semaglutide produced substantial weight loss — results that, according to reporting by Applied Clinical Trials Online, showed over 20% weight loss in the majority of participants. That's a bar semaglutide alone has not consistently cleared.
The REDEFINE 2 trial looked at the same combination in adults who also had type 2 diabetes — a population where weight loss is typically harder to achieve. Both papers were published on August 14, 2025, in the New England Journal of Medicine.
Meanwhile, Clinical Trials Arena reported that CagriSema outperformed Ozempic in Phase 3 — a direct head-to-head framing that underscores just how significant the gap appears to be.
Where It Stands Regulatorily
BioSpace reported in December 2025 that Novo Nordisk has filed CagriSema for FDA approval. That means the agency is now reviewing the data — though no approval date has been confirmed.
On ClinicalTrials.gov, a Phase 3 study comparing different formulation versions of injectable CagriSema is listed as not yet recruiting, suggesting Novo Nordisk is already preparing for commercial-scale delivery. Perhaps more notably, a Phase 3 trial studying CagriSema and cagrilintide in children and adolescents with excess body weight is actively recruiting — which signals how broadly Novo Nordisk is thinking about this drug's eventual reach.
The Side Effect Picture
CagriSema hasn't been FDA-approved yet, so there's no official label to cite. But semaglutide — the GLP-1 half of the combo — has a well-established profile. The FDA's Wegovy label lists the most common reported adverse reactions (occurring in 5% or more of users) as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, and dizziness, among others. Serious warnings include a reported risk of thyroid C-cell tumors (seen in animal studies), acute pancreatitis, gallbladder disease, and kidney injury from dehydration.
Whether cagrilintide meaningfully adds to that side effect burden — or changes the profile — is something the FDA review will scrutinize closely. The 2024 meta-analysis in Indian Journal of Endocrinology and Metabolism did examine safety signals for the combination, which will be important context for regulators.
What This Means for You
- CagriSema is not yet approved. If you're currently on Wegovy, Ozempic, or another GLP-1, nothing changes right now — but this pipeline drug is worth watching, especially if you've plateaued.
- The dual-hormone approach is genuinely new. Stacking amylin and GLP-1 signals is a different strategy than simply increasing the semaglutide dose, and the REDEFINE trial data published in the New England Journal of Medicine suggests the combination may outperform semaglutide monotherapy.
- Ask your prescriber, not the internet, about what's next for you. The FDA review is ongoing, and your individual health history — especially if you have type 2 diabetes or cardiovascular disease — matters enormously for which treatment is right.
Not medical advice. Talk to your prescriber about your situation.
